Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
about
Atypical antipsychotics for disruptive behaviour disorders in children and youthsRisperidone for disruptive behaviour disorders in children with intellectual disabilitiesPrescribing psychotropic drugs to adults with an intellectual disabilityEconomic cost of autism in the UKBehavioral and pharmacogenetics of aggressive behavior.Brain serotonin receptors and transporters: initiation vs. termination of escalated aggressionThe Problem Behaviour Checklist: short scale to assess challenging behavioursChanges in Heart Rate Variability Recorded in Natural Situation with T-Shirt Integrated Sensors and Level of Observed Behavioral Excitation: A Pilot Study of Patients with Intellectual Disabilities and Psychiatric Disorders.Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.Anger management for people with mild to moderate learning disabilities: study protocol for a multi-centre cluster randomized controlled trial of a manualized intervention delivered by day-service staff.Primary care of adults with developmental disabilities: Canadian consensus guidelines.Social validity of randomised controlled trials in health services research and intellectual disabilities: a qualitative exploration of stakeholder views.Experiences with general practitioners described by families of children with intellectual disabilities and challenging behaviour: a qualitative study.Caregiver Training in Mindfulness-Based Positive Behavior Supports (MBPBS): Effects on Caregivers and Adults with Intellectual and Developmental DisabilitiesIntellectual disability and mental health problems: a qualitative study of general practitioners' views.Treating Individuals With Intellectual Disabilities and Challenging Behaviors With Adapted Dialectical Behavior TherapyAssessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.The relationship between challenging behaviour and mental ill-health in people with intellectual disabilities: a review of current theories and evidence.Challenging behavior and related factors in people with intellectual disability living in residential care centers in Israel.International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.Unlicensed applications of licensed psychotropic drugs in an intellectual disability clinical service: retrospective case-note study.Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems.Social inclusion and people with intellectual disability and challenging behaviour: a systematic review.Treatments for the challenging behaviours of adults with intellectual disabilities.Treatment of behavioral problems in intellectually disabled adult patients with epilepsy.The neurobiology of aggression: implications for the pharmacotherapy of aggressive challenging behaviour by people with intellectual disabilities.Polypharmacy in the treatment of subjects with intellectual disability.Atypical antipsychotics for disruptive behaviour disorders in children and youths.Nidotherapy compared with enhanced care programme approach training for adults with aggressive challenging behaviour and intellectual disability (NIDABID): cluster-randomised controlled trial.Reductions in aggression and violence following cognitive behavioural anger treatment for detained patients with intellectual disabilities.Successful management of difficult-to-treat aggression with low-dose propranolol in a patient with intellectual disability: a case report.Psychotropic medication in children and adolescents.ASD, ADHD, mental health conditions and psychopharmacology in neurogenetic syndromes: parent survey.Towards the prevention of behavioural and psychiatric disorders in people with intellectual disabilities.Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.Behaviour Problems in Children with Intellectual Disabilities in a Resource-Poor Setting in India - Part 1: Association with Age, Sex, Severity of Intellectual Disabilities and IQ.A component analysis of positive behaviour support plans.The mediating effect of severity of client aggression on burnout between hospital inpatient and community residential staff who support adults with intellectual disabilities.Characteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data.Association of aggressive behaviours with psychiatric disorders, age, sex and degree of intellectual disability: a large-scale survey.
P2860
Q24200361-1F6FF32B-2FC1-4659-AB37-A65E77C05BBAQ24202324-F02F362A-EDD0-4EA5-80F2-1B39BEA362C5Q28075485-0CFF7F4B-256D-4988-8652-F693B38D355FQ28241419-B14DFDFB-E055-49C7-99DC-F9F81E9E6404Q30445754-735D3EA5-6BDB-4D61-BDFB-0CA3163CD8C2Q30453470-CCAC9646-B1B7-4F89-AF71-8906B1C2B6B6Q30490047-BC0D1074-017C-4F99-96EC-B900B5B99FFDQ33443611-24E78CD5-6CE2-483B-A66A-0524D59B11CBQ34194447-A8D79CAB-E2A1-494C-BD0E-50056393379EQ34610884-BE26DC52-C931-49B0-BC9A-0146440716B4Q34978203-0587E553-96D7-4957-AB19-7F4117B9333EQ35102852-39EB5274-F7EC-447C-90FF-E4C786122B47Q35577336-CD77DF45-D878-4CCE-BF0A-115355A3B98EQ36560297-25F8C903-0BA7-4CAE-BADA-4956606572E0Q36730157-D8ED94DC-2CD6-4003-897A-9F7290168D4AQ37051444-30684402-CDBC-4753-AC22-57443A147ABEQ37087389-DACE1E6A-0BC6-4163-A77F-075443605203Q37346920-0D7ACFF6-E1CB-45F8-A2CA-F80C6C80BD3AQ37372528-6358EB2B-D53D-47A1-943B-EC9B3381D434Q37379161-40A1A08F-1E01-429F-9234-94D329D8AAC2Q37808317-DCE923B6-23B7-460D-8653-65F03F4F29F0Q37820701-654CA715-6F0F-440B-A21A-B574C3370EE2Q38045902-70845E84-4F1C-42FB-B2B5-002C64B043C8Q38052700-91C20896-49B1-46C0-B7BC-5EF3076DB768Q38086302-A9F8A451-402F-430D-AAAE-D3670D455E29Q38182182-732BE5C0-32D1-4B6F-B340-DCFCAA3640DAQ38214474-038C4D6A-7579-4AAD-8A72-73372264E814Q38632745-9BD46BD3-8486-4FDD-A912-A4E1712443BEQ38998157-C5EDE463-734A-4A33-A9AA-02D28B95416EQ40621440-2FAFE32D-C3BE-41D1-A2A2-37CE7DEB7AC7Q41767521-A9A0D5FF-C7DB-4003-AEE3-F2D1A2F07467Q42413463-0C72A8EF-C24F-4461-ADD3-B6A82D092CD2Q44163889-24873BFD-D4E4-43C1-97B2-813AC3A6D23BQ44966878-A45052A4-233E-44C6-8C2B-09F775E3B7EAQ47640531-CB009032-8BAE-44B3-8208-99F98ECC17DEQ47973916-AF157B5F-2084-48F6-B257-593067FD92CEQ48404387-15DA35FE-DD59-43BE-9904-986ECDAC14EEQ50144955-BBDF0B31-426F-4A20-8466-64D49C951B85Q50301160-7CF1D1B4-DB8C-47B8-9EEC-7454DA2F9A1AQ50311393-8D9AEB1C-F86F-4273-9B5B-78F318EAD85C
P2860
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Risperidone, haloperidol, and ...... a randomised controlled trial.
@en
Risperidone, haloperidol, and ...... a randomised controlled trial.
@nl
type
label
Risperidone, haloperidol, and ...... a randomised controlled trial.
@en
Risperidone, haloperidol, and ...... a randomised controlled trial.
@nl
prefLabel
Risperidone, haloperidol, and ...... a randomised controlled trial.
@en
Risperidone, haloperidol, and ...... a randomised controlled trial.
@nl
P2093
P50
P921
P1433
P1476
Risperidone, haloperidol, and ...... a randomised controlled trial.
@en
P2093
Adrienne Regan
Bernard North
Bharti Rao
David Thomas
Joseph Eliahoo
Kofi Kramo
Michael Meade
Mike Crawford
P356
10.1016/S0140-6736(08)60072-0
P407
P577
2008-01-01T00:00:00Z